Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review

Oncology Nursing Forum
Debra B Gordon

Abstract

To review the dose titration, efficacy, and safety of oral transmucosal fentanyl citrate (OTFC). Phase I and II clinical trial abstracts and evidence-based review articles. OTFC has an onset, peak, and duration of action similar to that of an IV dose of an opioid and has been demonstrated to be effective and well tolerated for the management of breakthrough pain in patients with cancer. Studies of OTFC demonstrate that it is easy to use,noninvasive, effective, safe, and acceptable to patients, caregivers, and healthcare providers. However, OTFC is expensive and approved for use only in opioid-tolerant patients with cancer. Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat. Oncology nurses should familiarize themselves with OTFC's unique characteristics to be able to best help patients manage their therapy.

References

May 1, 1975·British Medical Bulletin·C A Squier, N W Johnson
Jun 1, 1990·Pain·R K Portenoy, N A Hagen
Aug 1, 1991·Anesthesiology·J B StreisandT H Stanley
Nov 1, 1990·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·M A AshburnT H Stanley
Sep 1, 1988·Clinical Pharmacology and Therapeutics·D S WeinbergK M Foley
Feb 1, 1987·Journal of in Vitro Fertilization and Embryo Transfer : IVF·A M LehtinenJ Hovorka
Nov 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M A Ashburn, J B Streisand
May 1, 1996·Journal of Pain and Symptom Management·F M Ferrante
Oct 14, 1998·Journal of Pain and Symptom Management·P G Fine, M A Busch
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M ChristieR K Portenoy
May 8, 1999·The American Journal of Hospice & Palliative Care·S Chandler
Aug 23, 2001·Journal of Pain and Symptom Management·R PayneR K Portenoy
Jan 5, 2002·Comprehensive Therapy·R Zimmer, M A Ashburn
Feb 22, 2002·Cancer·Sebastiano MercadanteUNKNOWN Steering Committee of the European Association for Palliative Care (EAPC) Research Network
Jul 20, 2002·International Journal of Palliative Nursing·Elizabeth Rees
Aug 17, 2002·Journal of Pain and Symptom Management·Xavier Gómez-BatisteHelena Camell
Jun 6, 2003·The Journal of Surgical Research·Eddy C HsuehDonald L Morton
Nov 19, 2003·The Journal of Pain : Official Journal of the American Pain Society·Barry V FortnerRussell K Portenoy
Jan 30, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lauren ShaiovaRussell K Portenoy
Apr 30, 2005·Journal of Palliative Medicine·P G Fine, J B Streisand

❮ Previous
Next ❯

Citations

Sep 1, 2006·Photomedicine and Laser Surgery
Oct 2, 2009·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Ramune JacobsenLona Christrup
Feb 7, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Bill H McCarberg
Aug 29, 2007·Clinical Journal of Oncology Nursing·Carol Proud
Sep 19, 2014·PloS One·Carlos A ValdezBrian P Mayer
Apr 23, 2015·International Journal of Palliative Nursing·Scott HandsakerCarole Fabby
Feb 5, 2009·Scandinavian Journal of Caring Sciences·Bettina S HuseboAnne E Ljunggren
Jan 1, 2013·Social Marketing Quarterly·Scott A DamonPeyton N Williams

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.